A Prospective Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer
The goal of this protocol is to determine mechanisms of resistance to epidermal growth
factor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) in non-small cell lung cancer (NSCLC). A
number of trials have shown small molecule kinase inhibitors to be active agents in the
treatment of NSCLC . Clinically these drugs have been noted to produce dramatic but
infrequent responses. Mutations in the epidermal growth factor receptor have been shown to
correlate with sensitivity to gefitinib and erlotinib[2,3]. However, we know that most
patients who have initial responses to EGFR-TKI eventually progress. The mechanism of
acquired clinical resistance to these inhibitors in patients incompletely understood.
This is a protocol to study clinical characteristics and biopsy tissue of patients with
non-small cell lung cancer who have had previous clinical response to small molecule kinase
inhibitors and subsequently experience progression of disease. The tissues and other
specimens will be used to carry out laboratory studies to explore the molecular basis of
sensitivity and resistance to small molecule kinase inhibitors.
Observational Model: Case-Only, Time Perspective: Prospective
To compare EGFR gene sequence in patients upon relapse with EGFR gene sequence prior to treatment with small molecule kinase inhibitors.
Gregory J Riely, MD
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
|Memorial Sloan Kettering Cancer Center||New York, New York 10021|
|Memoral Sloan Kettering Cancer Center||Basking Ridge, New Jersey|
|Memorial Sloan-Kettering Cancer Center @ Suffolk||Commack, New York 11725|
|Memoral Sloan Kettering Cancer Center at Phelps||Sleepy Hollow, New York 10591|
|Memorial Sloan-Kettering at Mercy Medical Center||Rockville Centre, New York|